We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ILEVRO (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
ILEVRO
Date registered
Evaluation commenced
Decision date
Approval time
229 working days (255)
Active ingredients
nepafenac
Registration type
EOI
Indication
ILEVRO (eye drops) is now also indicated for the reduction in risk of postoperative macular oedema associated with cataract surgery in patients with non proliferative diabetic retinopathy.